Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America

Helio S Sader; Robert K Flamm; Jennifer M Streit; Cecilia G Carvalhaes; Rodrigo E Mendes

doi:10.1016/j.ijid.2018.10.004

Back

Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America

Journal article

Open access

Peer reviewed

Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America

Helio S Sader, Robert K Flamm, Jennifer M Streit, Cecilia G Carvalhaes and Rodrigo E Mendes

International journal of infectious diseases, Vol.77, pp.82-86

12/2018

DOI: 10.1016/j.ijid.2018.10.004

PMID: 30315990

Files and links (1)

url

https://doi.org/10.1016/j.ijid.2018.10.004View

Published (Version of record) Open Access

Abstract

To evaluate the potency and spectrum of ceftaroline and comparator agents tested against contemporary bacteria isolated from patients with community-acquired bacterial pneumonia (CABP) in Europe (EUR), Asia-Pacific (APAC), and Latin America (LATAM). A total of 4321 bacterial isolates were collected consecutively by the SENTRY Antimicrobial Surveillance Program in 2015-2017 from 65 medical centers located in Western Europe (W-EUR; 21 centers in 10 nations), Eastern Europe and the Mediterranean region (E-EUR; 15 centers in 11 nations), APAC (18 centers in nine nations), and LATAM (11 centers in nine nations). Isolates were collected from lower respiratory tract specimens, and an isolate obtained from an outpatient or earlier than 48h after hospitalization was considered community-acquired. Organisms were tested for susceptibility by reference broth microdilution methods in a central laboratory. Among Streptococcus pneumoniae (n=1736), 99.9% of isolates were ceftaroline-susceptible (MIC , 0.008/0.12mg/l), and ceftriaxone susceptibility (≤1mg/l) ranged from 97.4% in W-EUR to 85.3% in the APAC region. Ceftaroline was also active against Haemophilus influenzae (n=1172; MIC , 0.008/0.03mg/l; 99.8%/93.9% susceptible per CLSI/EUCAST criteria) and Staphylococcus aureus (n=777; MIC , 0.25/1mg/l; 97.4% susceptible). Oxacillin resistance ranged from 31.9% in the APAC region to 15.0% in E-EUR. Ceftaroline also demonstrated potent activity against Moraxella catarrhalis (n=613; MIC , 0.06/0.25mg/l) and Haemophilus parainfluenzae (n=23; MIC , 0.015/0.03mg/l). Susceptibility rates varied widely by geographic region. Ceftaroline was active against the vast majority of bacterial organisms isolated from patients with CABP.

Anti-Infective Agents - pharmacology

Asia

Ceftriaxone - pharmacology

Cephalosporins - pharmacology

Clindamycin - pharmacology

Community-Acquired Infections - drug therapy

Community-Acquired Infections - microbiology

Drug Resistance, Multiple, Bacterial

Erythromycin - pharmacology

Europe

Haemophilus influenzae - drug effects

Haemophilus parainfluenzae - drug effects

Humans

Latin America

Levofloxacin - pharmacology

Microbial Sensitivity Tests

Moraxella (Branhamella) catarrhalis - drug effects

Penicillins - pharmacology

Pneumonia, Bacterial - drug therapy

Staphylococcus aureus - drug effects

Streptococcus pneumoniae - drug effects

Tetracycline - pharmacology

Trimethoprim, Sulfamethoxazole Drug Combination - pharmacology

Details

Title: Subtitle: Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America
Creators: Helio S Sader - JMI Laboratories
Robert K Flamm - JMI Laboratories
Jennifer M Streit - JMI Laboratories
Cecilia G Carvalhaes - JMI Laboratories
Rodrigo E Mendes - JMI Laboratories
Resource Type: Journal article
Publication Details: International journal of infectious diseases, Vol.77, pp.82-86
DOI: 10.1016/j.ijid.2018.10.004
PMID: 30315990
NLM abbreviation: Int J Infect Dis
ISSN: 1201-9712
eISSN: 1878-3511
Grant note: DOI: 10.13039/100004319, name: Pfizer
Language: English
Date published: 12/2018
Academic Unit: Pathology
Record Identifier: 9984183982002771

Metrics

20 Record Views

19 Times Cited - Web of Science